IL17A and experimental autoimmune encephalomyelitis: Kurarinone has the ability to inhibit IL-17 production by suppressing Th17 differentiation, which is one of the mechanisms of the pharmaceutical effect of kurarinone on rheumatoid arthritis and experimental autoimmune encephalomyelitis [26].